In the absence of SHARPIN, cells fail to properly regulate the deubiquitinase CYLD, leading to RIPK1-mediated cell death. Deletion of Cyld reverses the sensitivity of Sharpin -/cells to TNF-induced cell death, as well as the multi-organ inflammation and immune dysfunction observed in
Introduction 1
Linear or M1-linked poly-ubiquitin modifications play a major role in regulating immune 2 responses (1-3). This modification is catalyzed by the linear ubiquitin chain assembly complex 3 (LUBAC) E3 ligase, which consists of the catalytic component RNF31/HOIP in complex with two other 4 essential proteins with non-catalytic functions RBCK1/HOIL1 and SHARPIN (4-10). Linear 5 ubiquitination plays a key role in signaling downstream of several immune receptors including Tumor 6
Necrosis Factor Receptor Superfamily (TNFRSF) members, antigen receptors and pattern recognition 7 receptors (1, 11). In the case of TNFa (TNF), LUBAC components are rapidly recruited to TNFR1 8 following receptor ligation to ubiquitinate target molecules, providing scaffolding for the formation of 9 multi-molecular complexes that propagate signaling. One critical signaling complex assembled by linear 10 ubiquitin is the I-kB kinase (IKK) complex that phosphorylates I-kBa (5, 6, 12 ), a step required for 11 subsequent degradation of I-kBa and induction of NF-kB-dependent gene transcription. NEMO 12 (encoded by the Ikbkg gene), a structural component of the IKK complex, is modified by linear 13 ubiquitination and also possesses a linear ubiquitin-binding domain that facilitates oligomerization of the 14 IKK complex (5, 6, 12, 13) . Cells deficient in linear ubiquitination have impaired IKK activity and NF-15 kB signaling in response to TNF stimulation (5, (7) (8) (9) . Since IKK can phosphorylate substrates other than 16 I-kB (14-16), whether linear ubiquitin regulates NF-kB-independent pathways and their downstream 17 biological processes remains poorly understood. 18
Consistent with its role in the signaling of immune receptors, LUBAC components are critical 19 for proper immune regulation. Loss-of-function mutations in RNF31/HOIP and in RBCK1/HOIL1 in 20 humans cause immunodeficiency, autoinflammation, amylopectinosis, and lymphangiectasia (17, 18). In 21 mice, a loss-of-function mutation in Sharpin has been found in the chronic proliferative dermatitis 22 (cpdm) mice (hereafter referred to as Sharpin -/-), which spontaneously develops dermatitis, multi-organ 23 inflammation and displays immunodeficiency (7-9, 19-21). Crossing of Sharpin -/mice with Tnf -/mice 24 9 controls, these elevations were abrogated in the Sharpin -/-Cyld -/mice ( Figure 2F ). More modest changes 1 in serum IL2 and IL6, but not eotaxin and CCL3 (MIP-1a), were observed in the Sharpin -/mice 2 (Supplementary Figure S2F -I). Together, these data demonstrate that CYLD is critical for eliciting the 3 multi-organ inflammation and abnormal lymphoid tissues observed in the Sharpin -/mice, suggesting 4 dysregulated CYLD activity in the absence of SHARPIN. 5 6 CYLD phosphorylation is disrupted by SHARPIN deficiency. 7
The above results showed a clear genetic interaction between SHARPIN and CYLD but the 8 mechanistic relationship between the two molecules was unknown. Following TNFR1 ligation, an array 9 of signaling scaffold and effector molecules such as LUBAC, cIAP1/2, TRAF2, and IKK are recruited 10 to TNFR1. This receptor complex, also known as Complex I (55), propagates a survival signal. CYLD 11 can also be recruited to the receptor complex via a SPATA2-dependent association with RNF31/HOIP 12 (44-48). But how defects in linear ubiquitin could lead to CYLD activation was not known. CYLD is 13 regulated by post-translational mechanisms, and cleavage by CASP8 and MALT1 have been reported to 14 regulate its function (53, 56) . Another potential regulatory mechanism may be phosphorylation. CYLD 15 phosphorylation at a cluster of serine residues around Ser 418 carried out by IKKb in a stimulus 16 dependent fashion is known to suppress its enzymatic activity (43). Phosphorylation of CYLD at Ser 17 418 by IKKe was also reported to have the same effect (57). Since SHARPIN-deficient cells were 18 reported to have diminished IKK activity (8), we postulated that SHARPIN deficiency would also lead 19 to diminished CYLD phosphorylation, which would result in a more active CYLD to initiate cell death. 20
To test this, we examined the phosphorylation kinetics of CYLD in primary adult dermal fibroblast 21 (ADF). Using an antibody that detects phosphorylated Ser 418 of CYLD, we observed an induction in 22 CYLD phosphorylation in Sharpin +/+ cells but this phosphorylation was diminished in Sharpin -/cells 23 ( Figure 3A ). To confirm that the defect in CYLD regulation is caused specifically by SHARPIN 24 deficiency, we examined the SHARPIN-complemented MEF described in Supplementary Figure S1 . 1 Complementation of Sharpin -/cells with Sharpin, but not with a control gene, restored CYLD 2 phosphorylation ( Figure 3B ). Consistent with the previous study that IKKb phosphorylates CYLD (43), 3 blockade of IKKb with the highly selective chemical inhibitor [5-(p-Fluorophenyl)-2-ureido]thiophene-4 3-carboxamide (TPCA-1) resulted in reduced CYLD phosphorylation in Sharpin +/-MEF, similar to that 5 observed in Sharpin -/-MEF ( Figure 3C ). To extend our observations beyond fibroblasts, we examined 6 splenic B cells. Sharpin -/-B cells also showed diminished CYLD phosphorylation when compared to 7 their wild type counterparts ( Figure 3D ) though there appears to be some reduction in the level of CYLD 8 in the Sharpin -/-B cells. Similarly, in total splenocytes, CYLD phosphorylation was detected in 9
Sharpin +/+ but not in Sharpin -/cells ( Figure 3E ). Interestingly, blotting for CYLD revealed a significant 10 loss in full-length CYLD in the Sharpin -/splenocytes, accompanied by the detection of smaller 11 fragments of CYLD. CASP8 and MALT1 have been shown to cleave CYLD (53, 56, 58) . A 25 kD and 12 35 kD N-terminal fragment of CYLD that are products of CASP8-and MALT1-mediated proteolysis, 13 respectively, are detected in the Sharpin -/splenocytes. These observations suggest that compensatory 14 mechanisms to remove CYLD may be invoked in the face of SHARPIN deficiency to attain a cellular 15 state akin to deleting Cyld in the Sharpin -/-Cyld -/mice. These findings indicate that in Sharpin 16 deficiency, CYLD phosphorylation is impaired resulting in its initiation of cell death and that some cell 17 types may attempt to avoid this fate by removing CYLD through other mechanisms. 18
19

SHARPIN-deficient cells are more susceptible to CYLD-mediated cell death. 20
Since our earlier result in MEF showed a role for SHARPIN and CYLD in regulating cell death 21 (Supplementary Figure S1 ), we examined the sensitivity of ADF obtained from Sharpin +/+ , Sharpin -/-, 22
Cyld -/and Sharpin -/-Cyld -/mice to TNF-induced cell death. Sharpin -/-ADF were more susceptible to 23 TNF-induced apoptosis and necroptosis when compared to their Sharpin +/+ counterpart ( Figure 4A ). The 24 increased susceptibility to both forms of death was abolished in Sharpin -/-Cyld -/cells ( Figure 4A ), 1 consistent with observations obtained earlier by knocking down CYLD (Supplementary Figure S1 ). 2
Similarly, Sharpin -/-ADF exhibited enhanced apoptotic markers (i.e., cleaved CASP8, CASP3 and 3 PARP) and a necroptotic marker (i.e., phospho-MLKL) when compared to Sharpin +/+ ADF, and these 4 death signatures were diminished in the Sharpin -/-Cyld -/-ADF ( Figure 4B -E). Similar data were also 5 observed in MEF. Sharpin -/-MEF were more sensitive to apoptosis and necroptosis, which was reversed 6 in the Sharpin -/-Cyld -/-MEF (Supplementary Figure S3A -E). These results demonstrate that enhanced 7 sensitivity to cell death in SHARPIN-deficient cells is dependent on CYLD. CYLD initiates death-8 signaling by removing K63-linked ubiquitin chains from RIPK1 thereby converting RIPK1 from a 9 survival-signaling to a death-signaling effector (31, 53, 59) . This conversion is biochemically detected 10 by the translocation of RIPK1 to the FADD/CASP8 death-inducing signaling complex (DISC). We 11 therefore sought to confirm that there was more conversion of RIPK1 to its death-signaling form in 12 SHARPIN-deficient cells and that this was dependent on CYLD. In ADF treated with TNF, in the 13 presence of a combination of cycloheximide and zVAD-fmk to stabilize the DISC, RIPK1 was detected 14 in the FADD pulldowns of Sharpin -/-ADF more rapidly than in Sharpin +/+ cells ( Figure 4F ). RIPK1 15 translocation to the DISC was abrogated in Sharpin -/-Cyld -/-ADF ( Figure 4F ) demonstrating that CYLD 16 is necessary for the conversion of RIPK1 to a death-signaling molecule when SHARPIN is absent. The 17 dependence on CYLD for RIPK1 translocation to the DISC was also observed in MEF (Supplementary 18 Figure S3F ). We confirmed expression, or lack therefore, of SHARPIN and CYLD in the MEF of the 19 indicated genotype (Supplementary Figure S3G ). As an additional confirmation, we reconstituted 20 Figure S3H ) to that observed previously in ADF ( Figure 4F ) and MEF (Supplementary 23 Figure S3F ). 24
If Sharpin -/cells are more sensitive to death due to defective CYLD phosphorylation, then a 1 non-phosphorylatable CYLD mutant would be predicted to mimic the SHARPIN deficiency (i.e., more 2 sensitive to cell death). Mutations in the cluster of seven serines around residue 418 of human CYLD 3 was shown to result in a gain-of-function in deubiquitinase activity (43). We generated an analogous 4 mutant of mouse CYLD with seven serine to alanine substitutions (CYLD-S7A) and complemented 5
Cyld -/-MEF with either wild type or mutant CYLD. The complemented cells were treated with TNF in 6 the presence of zVAD-fmk in order to prevent CYLD cleavage by CASP8 (53) and thus negate the 7 potential confounding issue of differential cleavage of CYLD-WT versus CYLD-S7A by CASP8. Under 8 this stimulation condition, CYLD-complemented cells undergo necroptosis (53) and this death response, 9 quantified by PI staining, was enhanced in the CYLD-S7A-complemented cells as compared to CYLD-10 WT-complemented cells ( Figure 4G ). The CYLD-S7A-complemented cells phenocopied the SHARPIN-11 deficient cells (Supplementary Figure S1A & 1B) , consistent with the notion that phosphorylation and 12 therefore inhibition of CYLD, is a key regulatory event that suppresses cell death in response to TNF. 13
Our findings imply that there is dysregulated CYLD activity in SHARPIN-deficient cells. 14
15
CYLD-mediated death of myeloid cells causes skin inflammation 16
The leukocytic infiltration in the skin of the Sharpin -/mice consists of granulocytes and 17 macrophages (19) prompting us to examine the role of macrophages in the pathogenesis of skin lesions 18 in these mice. We recently reported that macrophages are highly susceptible to CYLD-dependent auto-19 necroptosis mediated by the TNF that is produced in response to TLR4 ligation (59). Bone marrow 20 derived macrophages (BMDM) deficient in SHARPIN showed a defect in CYLD phosphorylation when 21 stimulated with TNF ( Figure 5A we tested to see if these macrophages also exhibit altered necroptosis. In response to low-dose LPS that 1 elicits TNF-dependent necroptosis (59), Sharpin -/-BMDM were more sensitive to necroptosis compared 2 to their wild type counterparts and this was abrogated in the Sharpin -/-Cyld -/-BMDM ( Figure 5D ). A 3 similar effect was also observed using pIC to trigger necroptosis ( Figure 5E ). Analysis of DISC 4 formation showed that RIPK1 was detected in FADD pulldowns of Sharpin -/-BMDM more rapidly than 5
in Sharpin +/+ cells treated with TNF ( Figure 5F ). Similar to that observed previously in ADF ( Figure  6 4F), RIPK1 association with the DISC was abrogated in Sharpin -/-Cyld -/-BMDM. To confirm the in 7 vitro BMDM data, we looked for evidence of macrophage death in skin sections taken from mice of the 8 different genotypes. Consistent with a previous report showing apoptosis occurring in the skin of 9
Sharpin -/mice (60), we detected cleaved CASP3 in the skin of Sharpin -/mice, a proportion of which 10 co-localized with F4/80+ macrophages ( Figure 5G & H). However, cleaved CASP3 was largely absent 11 in the Sharpin -/-Cyld -/skin consistent with our in vitro data showing that SHARPIN-deficient cells 12 undergo cell death in a CYLD-dependent manner. 13
The genetic crosses conducted using germline knockouts showed CYLD to be the cause of the 14 phenotype observed in Sharpin -/mice. However, the contribution of CYLD-dependent death in specific 15 cellular compartments to the Sharpin -/phenotype is not clear. The data in Figure 5A -H prompted us to 16 ask whether CYLD-dependent macrophage death has any role in the pathogenesis of the Sharpin -/mice. 17
We crossed the Sharpin -/strain to the LysM-cre-driven conditional knockout of Cyld (Cyld M-KO ) we 18 previously generated (59). The Sharpin -/-Cyld M-KO mice showed significant improvement in their 19 dermatitis compared to the Sharpin -/mice, which develop discernable dermatitis by week 8 in our 20 colony ( Figure 6A ). In our cohort, two thirds of Sharpin -/-Cyld M-KO mice did not show skin inflammation 21 by week 16 while the remaining 1/3 had delayed progression (Supplementary Figure S4D ). Histological 22 analysis showed that the typical ulceration, thickening of the epidermis and leukocytic infiltration 23 observed in Sharpin -/skin was absent in Sharpin -/-Cyld M-KO mice with no disease ( Figure 6B ). However, 24 other defects in the spleen and thymus of Sharpin -/mice were not reversed in the Sharpin -/-Cyld M-KO 1 mice ( Figure 6C & D). We confirmed that BMDM generated from Sharpin -/-Cyld M-KO mice were more 2 resistant to cell death than those from Sharpin -/mice and that the LysM-cre was effective in knocking 3 out CYLD in our BMDM cultures (Supplementary Figure S4E -G). We also crossed the Sharpin -/strain 4 to a Cx3cr1-cre-driven conditional knockout of Cyld (Cyld MP-KO ), which targets mononuclear 5 phagocytes including macrophages (61). The Cx3cr1-cre-mediated deletion of Cyld recapitulated the 6 effect observed earlier with LysM-cre (Supplementary Figure S5A -G). Results from the use of two 7 different cre strains that can delete Cyld in macrophages led us to conclude that CYLD-dependent 8 macrophage cell death may be a major driver of the inflammatory response in the skin of the Sharpin -/-9 mice. This study now provides genetic data that could account for the Sharpin -/phenotype. We 2 propose that in wild type cells, SHARPIN-dependent regulation of CYLD suppresses its function, 3 allowing K63-linked ubiquitin chains on RIPK1 to be sustained thus preventing RIPK1 from becoming a 4 death-signaling molecule ( Figure 6E , left panel). Thus, SHARPIN-dependent inhibition of CYLD is an 5 essential component of Checkpoint 1 in the TNF signaling pathway that keeps cell death at bay. In the 6 absence of SHARPIN, there is a failure to suppress CYLD, which dismantles K63-linked ubiquitin 7 chains from RIPK1 to initiate the RIPK1-dependent death cascade ( Figure 6E , right panel). We note that 8 there is reduced phosphorylation of serine 418 of CYLD in SHARPIN-deficient cells, which is known to 9 be phosphorylated by IKKb and IKKe (43, 57). Reduced CYLD phosphorylation could be due to 10 reduced IKK activity in SHARPIN-deficient cells (7-9). In addition, CYLD is recruited to the receptor 11 complex in a SPATA2 and RNF31/HOIP-dependent manner (44-48) and since Sharpin -/cells have 12 reduced RNF31/HOIP level (7-9), this could reduce CYLD recruitment to the receptor complex and 13 subsequent phosphorylation by IKK. In light of published studies that phosphorylation of CYLD at a 14 cluster of serines around residue 418 inhibits its enzymatic activity (43, 57), it is likely that the defective 15 phosphorylation of CYLD in the SHARPIN-deficient cells enhanced CYLD's removal of ubiquitin 16 chains from RIPK1. Alternatively, phosphorylation could regulate CYLD function in a non-enzymatic 17 manner such as regulating its localization or its interaction with signaling partners. Furthermore, it is 18 possible that SHARPIN could inhibit CYLD through some other mechanism independent of 19 phosphorylation and this will be further explored. 20
In addition to phosphorylation, CYLD can also be negatively regulated by proteolysis mediated 21 by CASP8 and MALT1 (53, 56) . Interestingly, SHARPIN-deficient splenocytes may circumvent the 22 defect in CYLD phosphorylation by upregulating these proteolytic events suggesting that these 23 inhibitory mechanisms could compensate for each other. Furthermore, CYLD can be phosphorylated by 24 multiple members of the IKK family including IKKb, IKKe and TBK1 suggesting that there may be 1 redundancy in regulating CYLD phosphorylation in different cell types. This redundancy could explain 2 the modest defect in CYLD phosphorylation in the Sharpin -/-BMDM as macrophages express IKKe and 3 TBK1 (62). Besides CYLD, these IKK kinases also directly phosphorylate RIPK1 to inhibit the death-4 signaling function of RIPK1 (26-30). Taken together, the emerging picture is that a fully functional 5
Checkpoint 1 needed to suppress ripoptocide is dependent on multiple post-translational modification of 6 several molecules. 7
Biologically, these results really point towards suppression of CYLD as central to immune 8 homeostasis as perturbation in CYLD regulation, as observed in the Sharpin -/mice, leads to multi-organ 9 inflammation and disruption of lymphoid tissues. It also demonstrates that CYLD functions as a pro-10 inflammatory molecule since its deletion resolves the inflammation seen in the Sharpin -/mice. These 11 aspects of CYLD in the proper functioning of the immune system have not been appreciated to date. 12
Previous studies with CYLD have described it as having an anti-inflammatory function (63-65), 13 primarily because of its inhibitory effect on the NF-kB pathway. We now show that CYLD can be 14 highly pro-inflammatory via its death-inducing function, which is revealed upon the loss of an upstream 15 inhibitory mechanism (e.g., SHARPIN/LUBAC). This is a significant advance in our understanding of 16 the role played by ubiquitin-modifiers in regulating immune homeostasis and response. Our studies 17 strongly suggest that the defects observed in human patients with mutations in RNF31/HOIP and 18 RBCK1/HOIL1 (17, 18) could be due to inappropriate CYLD activity. 19
Excessive CYLD-dependent cell death in the Sharpin -/mice can cause skin inflammation due to 20
(1) death of epithelial cells that could result in cellular erosion and ulcers in and of itself, (2) loss of 21 barrier function in the epithelial layer and subsequent breach by commensal microbiota and 22 environmental contaminants (bedding and food), and/or (3) excessive cellular debris from dying cells 23 that are not properly cleared by phagocytes. The reversal of skin inflammation in Sharpin -/mice 24 following deletion of Fadd or Tradd in keratinocytes indicates that cell death in this cellular 1 compartment is critical for inflammation (22) . Our observation that the skin inflammation was also 2 reduced by LysM-cre-and Cx3cr1-cre-mediated deletion of Cyld suggested that cell death of 3 macrophages also has a pro-inflammatory function. One explanation is that death of Sharpin -/epithelial 4 cells is the initiating factor for the skin inflammation while death in macrophages plays an accessory 5 role. SHARPIN-deficient macrophages can contribute to the skin inflammation by undergoing more 6 death in response to invading microbiota and thereby amplifying the inflammatory response. 7
Alternatively, because SHARPIN-deficient macrophages are more sensitive to death, they may be less 8 effective in clearing up debris from dying epithelial cells. Since both LysM-cre-and Cx3cr1-cre-9 mediated deletion of Cyld had the same effect, our data strongly suggest that improper cell death in 10 macrophages is highly inflammatory in the skin but does not have a role in other immune dysfunction in 11
the Sharpin -/mice such as the disruption in splenic architecture. 12
The Sharpin -/mouse illustrates the pathophysiology when the TNF response switches from cell 13 of TNF/CYLD-mediated ripoptocide is inflammation. In particular, the invocation of this death response 20 in macrophages is highly inflammatory since blocking this from occurring in macrophages ameliorated 21 the skin inflammation of the Sharpin -/mice. Therefore, it is probable that the inflammation caused by 22 ripoptocide has an anti-microbial function, as previously postulated (67). Since CYLD's death-inducing 23 function can be controlled by post-translational modifications, the speculation is that this early 24 transcription-independent molecular switch may be disrupted by pathogens, thus providing a facile and 1 rapid switch to cell death to generate an inflammatory response beneficial to the host. The IKK complex 2 that phosphorylates CYLD is also necessary for induction of NF-kB-dependent inflammatory genes. 3 Therefore, pathogens may encode inhibitors to block IKK as a strategy to limit the host expression of 4 inflammatory genes and in so doing would also impair CYLD phosphorylation. This would be expected 5
to unleash CYLD-dependent ripoptocide and the ensuing inflammation would function as a 6 countermeasure against blockade of inflammatory gene induction by pathogens. It was particularly 7
interesting that blocking CYLD-dependent ripoptocide in macrophages had a strong anti-inflammatory 8 effect on the dermatitis of the Sharpin -/mice. These sentinel cells are the major producers of 9 inflammatory cytokines in response to infection and are also often the host for replicative parasitic 10 pathogens. Therefore, the presence of this CYLD-regulated 'trap door' in macrophages would be 11 advantageous to the host. An example of this is infection by the bacteria pathogen Yersinia. It encodes 12 an effector molecule YopJ to block cytokine gene synthesis, which likely leads to the disruption of 13 Checkpoint 1 to trigger ripoptocide and this has been shown to be beneficial to the host (29, 68). It is 14 likely that there are other pathogens that behave similarly. 15
In summary, we have uncovered the mechanistic basis for the immune dysfunction observed in 16 linear ubiquitin-deficient mice. This involves a defect in regulating CYLD, a molecular switch that is 17 normally turned off to prevent TNF from inducing death. The finding that linear ubiquitin regulates the 18 function of CYLD, an enzyme that dismantles K63-linked ubiquitin chains, reveals positive 19 cooperativity between the two forms of ubiquitin modifications in regulating a cellular response. In 20 addition to providing an explanation for the immune system abnormalities caused by genetic defects in 21 Skins, spleens, colons and small intestines were removed, fixed in 10% neutral-buffered formalin, and 9 then transferred into 70% ethanol. Paraffin embedding, tissue sectioning, H&E staining and 10 immunohistochemistry were performed by the Comparative Pathology Lab in the Center for 11
Comparative Medicine and Surgery, or by the Biorepository and Pathology CoRE at the Icahn School of 12
Medicine at Mount Sinai. Immunofluoresence labeling of skin sections was carried using the protocol 13 previously described (70). 14
Clinical scoring 15
The gross scoring scheme was modified from a system developed for a different mouse disease, 16 ulcerative dermatitis that occurs in C57BL/6 substrains (71). The clinical score combines gross 17 evaluation with histologic scoring from skin sections. In brief, 4 criteria were evaluated: character of 18 lesion (0=none, 1=alopecia or excoriations only, or 1 small punctuate crust, 2=multiple, small punctuate 19 crusts or coalescing crusts (>2mm), regions affected (head/cervical, thoracic, and/or abdominal/caudal; 20 0=none, 1=<25%, 2=25-50%, 3=>50%). The "regions affected" score in Hampton et al (71) was based 21 on the progression of the disease. Ulcerative dermatitis in B6 mice often started in the 22 intercapsular/dorsal back area (region 2) and progressed, thus encroachment on the head and face 23 (region 1) was considered to be a severe score. In this study, the lesions often start in the ventral 1 chin/neck region (region 1) and progress to the thorax, abdomen and back. The scoring system was 2 modified to increase in severity based on the number of regions affected rather than the specific region 3 affected because of this difference in progression of skin disease. For the histologic lesions, scoring was 4 a subjective 0=none, 1=mild, 2=moderate, 3=marked scale. The scoring of inflammation in the 5 dermatitis was done using the following scale 0=none, 1=mild (focal or few foci of inflammation in 6 superficial dermis), 2=moderate (multiple foci with inflammation in deep dermis, with or without 7 ulcerations), and 3=severe (regionally extensive with inflammation extending to the subcutis and 8 ulceration). 9
Serum immunoglobulins, cytokines and chemokines assessment 10
Blood was collected via facial vein from 10-16 weeks old mice and spun at 1000 x g for 10 min at room 11 temperature. Serum was then collected and stored at -80°C. IgA, IgE, IgG and IgM in the serum were 12 quantified using multiplex LuminexÒ Immunoglobulin Isotyping. IFNG, IL2, IL5, IL6, IL12/23p40, 13 eotaxin and CCL3 (MIP-1a) in the serum were quantified using LuminexÒ Cytokines and Chemokines 14 Multiplex Assays. 15
Stool IgA assessment 16
Stool pellets obtained from 10-16 week old mice were placed in chilled PBS containing protease 17 inhibitors (100 mg/ml), repeatedly smashed and vortexed for 4-5 times. The suspension was then 18 centrifuged at 8000 x g for 10 min at 4 °C. The supernatants were collected and frozen at -80°C. IgA 19 levels were quantified using the Mouse IgA ELISA Quantitation Set (Bethyl Laboratories).
A small section (2 mm x 3 mm) of the ears from adult mice were snipped, soaked in 70% ethanol for 30 1 sec and washed with sterile PBS. Tissues were then diced in culture media (DMEM with 10% FBS and 2 antibiotics) and spun down. The pellets were trypsinized for an hour at 37 °C with intermittent hard 3 vortexing prior to centrifugation. The pellets were then plated onto a tissue culture dish and cultured in 4 DMEM with 10% FBS and antibiotics at 37°C with 5% CO2 for 1-2 weeks. 5
Total splenocytes and B cell isolation 6
Spleens from 8-12-week-old adult mice were mashed and filtered through 70 µM sterile funnel and with 7 RBC lysis buffer for 5 min. Total splenocytes were then rested at 37 °C in a 5% CO2 incubator for at 8 least 2h before use. For B cell preparation, total splenocytes were subjected to negative selection using 9
BioLegend MojoSort Magnetic Cell Separation kit to obtain purified B cells. The purity was determined 10 by labeling for CD19 or CD40 by flow cytometry (>90%). B cells were rested for at least 2h before use. 11
Bone marrow-derived macrophage cultures 12
Bone marrow-derived macrophages (BMDM) were generated by culturing bone marrow progenitors 13 from femurs and tibias of mice in RPMI containing 10% FBS and 30% L929 conditioned medium as 14 described (72). Day 8 to 11 cultures were used for all experiments. 15
Retroviral transduction of MEF 16
HEK293 EBNA cells were transfected by calcium phosphate precipitation with plasmids encoding 17 VSV-G and GAG-POL, together with an MMLV-based retroviral expression construct encoding control 18 or relevant genes. 48 h post-transfection, the viral supernatants were collected and used to infect MEF 19 by spinoculation. MEF were selected with puromycin or blasticidin 24 h subsequently. Sharpin -/-MEF 20
were complemented with a negative control or wild type mouse Sharpin gene. Both lines were 21 asecondarily transduced with control or IkBSR to block NF-kB signaling. Sharpin -/-Cyld -/-MEF were 22 complemented with (i) control gene, (ii) mouse Sharpin wild type alone, (iii) mouse Cyld wild type 1 alone, or (iv) both mouse Sharpin and Cyld wild type alleles. Cyld -/-MEF were complemented with (i) 2 control gene, (ii) mouse Cyld wild type allele, or (iii) mouse Cyld S7A mutant allele. The Cyld S7A ser-to-ala 3 mutations were generated using Quikchange Multi Site-Directed Mutagenesis Kit (Agilent). 4
CYLD knockdown in MEF 5
HEK 293 EBNA cells were transfected by calcium phosphate precipitation with plasmids encoding 6 VSV-G and GAG-POL, together with MissionÒ shRNA lentiviral vectors targeting CYLD or a non-7 targeting shRNA. Lentiviral infection of Sharpin -/-MEF was carried out as described above for 8 retroviral transduction. 9
Cell death assays 10
Cellular death analyses were performed by Annexin V or propidium iodide staining and flow cytometry 11 as previously described (53) . Cell death was also quantified using the CellTiter-Glo Luminescent Cell 12
Viability Assay (Promega). Biological triplicates were used in the experiments for ADF and BMDM cell 13 death analysis. 14
Co-immunoprecipitation 15
For FADD immunoprecipitation, 2 x 10 6 cells ADF and MEF or 3-4 x 10 6 BMDM per sample were 16 Cocktail Set V for 20 min on ice. Lysates were cleared by centrifugation at 10, 000 x g at 4°C. One tenth 6 of the lysate was set aside for SDS-PAGE and sequential blotting with anti-RIPK1 and anti-ACTIN. The 7 reminder of the lysates was immunoprecipitated by rotating with 0.4 µg of RIPK1 antibody overnight at 8 4°C. Immune complexes were precipitated with Protein A/G beads. After extensive washing, the beads 9
were eluted with SDS-sample buffer at 70°C for 20 min. Blotting with anti-RIPK1 was carried out 10 subsequently. 11
Western blot Analysis 12
Cellular lysates obtained using 1% Triton X-100 were resolved by reducing SDS PAGE. For P-MLKL, 13 lysates were generated using M2 buffer as previously described (73). Blotting was conducted using 14 standard techniques and detected by LiCor Odyssey or by chemiluminescence. Semi-quantification of 15 the blots was carried using Image J software (74) . 16
Statistical Analysis 17
Statistics were performed using one-way Anova, Student's t-test or Mann Whitney U test. (*p<0.05, 18 **p<0.01, ***p<0.001) 19
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